Hepatology

Obesity and diabetes mellitus are widely acknowledged risk factors for the development of steatotic liver diseases, contributing to liver cirrhosis and HCC.

Cirrhosis-associated immune dysfunction heightens infection susceptibility through low-grade systemic inflammation and gut-liver axis alterations.

This study demonstrates that combining vibration-controlled transient elastography with retina scanning offers a practical strategy for identifying individuals with potential liver fibrosis.

These findings suggest that dihydroxyacetone phosphate, along with alanine transaminase, could serve as a valuable non-invasive biomarker for liver fibrosis.

These disruptions may play a pathophysiological role in metabolic dysfunction-associated steatotic liver disease development.

Recent research highlights the discovery of 17 novel loci associated with liver triglycerides and 9 linked to liver inflammation.

Recent studies have highlighted the potential of sodium-glucose cotransporter 2 inhibitors, especially ertugliflozin, in improving outcomes for patients with NAFLD and T2DM.

Frailty has emerged as a therapeutic target in advanced chronic liver disease management, with non-pharmacological interventions showing promise.